Multiply Labs specializes in advanced robotic systems designed for the manufacturing of precision medicines, particularly in the cell therapy sector. Their technology enables the production of gene-modified cell therapies at an industrial scale, ensuring compatibility with leading Good Manufacturing Practice (GMP) instruments. The flexibility of their robotic systems allows users to select combinations of modules tailored to specific processes, while high-throughput capabilities are achieved by operating multiple modules in parallel. This innovative approach aims to provide every patient with access to next-generation medicines, positioning Multiply Labs as a leader in the pharmaceutical manufacturing landscape.

A key component of Multiply Labs' technology is their Digital QC (Quality Control) system, which automates data collection and creates comprehensive digital records for each drug product. This system is compliant with CFR Part 11 regulations and operates both on-premises and in the cloud, ensuring 100% traceability of manufacturing processes. Digital QC facilitates a shift from traditional post-process quality control to advanced in-process monitoring, capturing an unprecedented amount of process data. The system's Dashboard interface allows manufacturing teams to schedule jobs, set parameters, and monitor robotic operations in real-time, while the Planner optimizes the efficiency of the robotic systems by managing the allocation of tasks and maximizing throughput.

United States

Multiply Labs develops advanced robotic systems that manufacture individualized drugs at scale. Our products are enabled by the combination of pharmaceutical science with robotics technology.

Multiply Labs has built and operates a unique robotic pharmaceutical manufacturing facility in San Francisco.

Multiply Labs

Company Details